Journal of Experimental & Clinical Cancer Research (Aug 2009)

Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients

  • Takeda Hiroshi,
  • Kidani Akihiko,
  • Yoshimura Hiroshi,
  • Kanazawa Akiyoshi,
  • Katano Kuniyuki,
  • Sugimoto Shinichi,
  • Makino Masato,
  • Ozaki Nobuhiro,
  • Tanaka Tsuneo,
  • Ikeguchi Masahide

DOI
https://doi.org/10.1186/1756-9966-28-109
Journal volume & issue
Vol. 28, no. 1
p. 109

Abstract

Read online

Abstract Background Combination chemotherapy with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) has become a standard regimen for colorectal cancer. An increase of adverse events with combination chemotherapy is predicted in elderly patients, and it remains controversial whether they should receive the same chemotherapy as younger patients. Accordingly, this study of modified FOLFOX6 (mFOLFOX6) therapy was performed to compare its safety between elderly and non-elderly patients. Methods We prospectively studies 14 non-elderly patients aged Results The main adverse events were neutropenia and peripheral neuropathy, which occurred in 62.5% (≥ grade 3) and 87.5% (≥ grade 1) of elderly patients. The grade and frequency of adverse events were similar in the elderly and non-elderly groups. In some patients with neutropenia, treatment could be continued without reducing the dose of oxaliplatin by deleting bolus 5-fluorouracil. A correlation was found between the cumulative dose of oxaliplatin and the severity of neuropathy, and there were 2 elderly and 3 younger patients in whom discontinuation of treatment was necessary due to peripheral neuropathy. The median number of treatment cycles was 10.0 and 9.5 in the non-elderly and elderly groups, respectively. The response rate was 60.0% in the non-elderly and 50.0% in the elderly group, while the disease control rate was 100% and 83.3% respectively, showing no age-related difference. Conclusion mFOLFOX6 therapy was well-tolerated and effective in both non-elderly and elderly patients. However, discontinuation of treatment was sometimes necessary due to peripheral neuropathy, which is dose-limiting toxicity of this therapy.